← All trials
NCT03130114
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 13, 2017
- Primary completion
- Dec 31, 2020
- Completion date
- Dec 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 11500
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- World Health OrganizationLead sponsor
- Kenya Medical Research InstituteCollaborator
- University of WashingtonCollaborator
- International Center for Diarrheal Disease ResearchCollaborator
- University of LiverpoolCollaborator
- University of MarylandCollaborator
- Aga Khan UniversityCollaborator
- World Health OrganizationSponsor investigator
- World Health OrganizationStudy director
- Centre pour le developpement des vaccines, MaliCollaborator
- Wellcome TrustCollaborator
- Harvard UniversityCollaborator
- Muhimbili UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.